| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
4 companies
Johnson & Johnson serves as a 10% Owner at NERV and has filed Form 4s across 4 companies. Across recent SEC filings that breaks down to 3 buys and 11 sells. Those positions are worth an estimated $1.4B at current prices.
Historically, Johnson & Johnson's trades have earned a middling insider score of 59/100 across 7 rated trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +0.3%.
The biggest single holding is JNJ (~$1.0B) as 10% Owner. The recent filings there lean toward selling, a net 18,718,905 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 13, 2015 | NERV Minerva Neurosciences, Inc. | 10% Owner | Buy | 607,903 | $4.81 | $2,924,013.43 | +15.6% |